The objective of the Legal and General UK Alpha Fund is to provide growth. The fund will typically invest between 90% and 100% in company shares from a small number…
On the hottest day on record for over 165 years, 30 CEOs and CFOs from many of the UK’s leading listed life science and healthcare companies made the journey to Westminster,…
AXA Investment Managers, one of the world’s largest asset managers, offers customised investment solutions across all major asset classes and regions. The AXA Framlington Biotech fund provides long-term capital appreciation by investing principally in equity securities…
In March, Jon Moulton increased his shareholding in Redx Pharma as the biotech company successfully completed it’s IPO on London’s AIM. Jon has long experience of turnarounds, having invested in…
For those of you not well versed in Latin, ‘Omne Trium Perfectum’ refers to the notion that everything that comes in threes is perfect or every set of three is…
Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The May issue is the third of 6 bi-monthly publications in 2015 aimed at providing insight,…
What follows is the final summary from the 22 April Biotechs and the City evening event, in which over 80 executives from across London, Cambridge and Oxford attended the ‘From…
What follows is the second summary from our evening panel discussion ‘From idea to IPO’ that took place at our most recent Biotechs and the City networking event. Panelists: Maina…
On 22 April, our ‘Biotechs and the City’ event, hosted by Nasdaq, welcomed over 80 delegates who were treated to an in depth discussion on strategies to help lifescience companies…
The following transcript comes from Obtaining growth capital and follow-on funding, a group discussion at February’s Biotech and Money London 2015 congress. Chairman and Panelists: Joe Pillman, Partner, Wilmer Hale (JP), Nigel…
